Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

lazertinib

lazertinib
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Lazcluze TABLET, ORAL 80 mg | 240 mg      
Comments:

Non-formulary. Defer initiation to the outpatient setting. Inpatients should use their home supply.

 

 

Reviewed: April 2025

 

Lazertinib (LAZCLUZE) Spotlight.pdf

Last updated: May. 14, 2025






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved